Related Experiment Video
Updated: May 19, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
1University of Maryland, School of Medicine, Marlene & Stewart Greenebaum Cancer Center, Leukemia & Hematologic Malignancies, Baltimore, MD 21201, USA.
Pharmacogenomics
|August 28, 2012
Summary
This review explores pharmacogenomics in acute myelogenous leukemia (AML) treatment, focusing on drug-metabolizing enzymes and transporters. It highlights how genetic factors influence patient response to chemotherapy and targeted therapies.
Area of Science:
- Hematology
- Pharmacogenomics
- Oncology
Background:
- Acute myelogenous leukemia (AML) is a complex cancer with diverse subtypes.
- Standard treatments like cytarabine and anthracyclines are not universally effective, especially in older adults or relapsed cases.
- Personalized medicine approaches are needed due to AML's heterogeneity.
Purpose of the Study:
- To review current knowledge on drug-metabolizing enzymes and transporters in adult AML.
- To discuss the role of pharmacogenomics in tailoring AML treatment.
- To highlight a specific gene signature for predicting response to farnesyltransferase inhibitors.
Main Methods:
- Literature review of pharmacogenomic studies in adult AML.
- Analysis of findings related to cytarabine and anthracycline metabolism and transport.
- Examination of genetic markers, including a two-gene signature (RASGRP1/APTX), for treatment response prediction.
Main Results:
- Drug-metabolizing enzymes and transporters significantly impact AML treatment efficacy.
- Pharmacogenomic variations can identify patient subsets who may benefit from specific therapies.
- A RASGRP1/APTX gene signature shows promise in predicting response to farnesyltransferase inhibitors.
Conclusions:
- Pharmacogenomic insights are crucial for optimizing AML treatment strategies.
- Personalized approaches considering genetic factors can improve outcomes for AML patients.
- Further research into pharmacogenomics will advance precision medicine in AML therapy.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...